GMA is the global / international marketing agency behind this page. The practical work is market-entry marketing: website, localization, proof, offer language, SEO/AI visibility, paid path, distributor follow-up, and sales material for the target buyer.
A Swiss-headquartered medtech holding carrying German production and Austrian R&D arrived in front of US hospital procurement with a CE-marked product, an MDR file calibrated for European notified-body evaluation, and a US website, deck, and sales material that did not survive the first FDA-aware procurement buyer. The engagement opened in Cross-Border Marketing Build and rolled into Global Marketing Partnership.
The Swiss holding ran a three-country operating shape. Group head office in German-speaking Switzerland, production in southern Germany, R&D in Austria. A multi-year CE pathway under EU MDR carried by an in-house regulatory affairs lead and a European notified-body relationship. Hospital-system installed base across Switzerland, Germany, Austria, and selected Benelux accounts. The owner/CEO voice on the home-market site was clinical-evidence-led and notified-body-careful.
The trigger was a US hospital pilot opening through a US distributor relationship. The hospital procurement office wrote back asking for the 510(k) submission status, the US regulatory point-of-contact, the predicate device used in the substantial-equivalence claim, the US-side clinical-evidence summary written for an FDA buyer, and a USD price presentation. The European MDR file, the clinical study pack, and the CE certificate were all in order. The US-facing layer was a translated home-market site that opened on the EU MDR story and did not name a US regulatory contact, a US predicate, or a US pricing reference.
US hospital procurement judges 510(k) status first. If the public website and sales material does not state it, the file is sorted into the unverified pile before clinical evidence is opened.
A US-resident regulatory contact carries more weight than the depth of the European notified-body relationship, regardless of MDR class.
CE-marked Class II devices entered the US 510(k) queue with median FDA decision timelines drifting toward six to ten months in recent cycles, per FDA premarket guidance.
The engagement opened as a Cross-Border Marketing Build, three to six months, scoped against the first product family and the active hospital pilot. The work covered the US-facing website, offer, proof, and follow-up end to end: public site, regulatory-posture page, US procurement deck, US-resident contact layer, owner/CEO LinkedIn for the group CEO and the US regulatory contact, RFQ template, and a US trade-publication posture for the next two quarters.
At month four the second product family entered FDA pre-submission. The engagement rolled into Global Marketing Partnership on a monthly retainer with a twelve-month minimum, scoped against ongoing US rebuild across the portfolio plus live support on procurement and FDA-adjacent commercial conversations. Pricing for both phases was confirmed after inquiry screening, not on the public site.
Mid-sized European medtechs entering the United States typically underestimate the procurement-clarity gap between MDR-aligned materials and an FDA-aware US hospital purchasing buyer. The clinical evidence is rarely the gating issue; the framing layer is.
| Surface element | Before the engagement | After the engagement |
|---|---|---|
| Opening fold | EU MDR pathway and notified-body history | 510(k) status, predicate claim, US contact |
| Regulatory contact | Swiss group regulatory lead, EU phone | US-resident regulatory affairs contact named |
| Clinical evidence pack | MDR Article 61 narrative | FDA-clear evidence summary |
| Pricing | EUR-denominated quotes on request | USD terms, US payment-term reference |
| Installed base reference | Switzerland, Germany, Austria, Benelux | One US pilot named, EU accounts as clinical posture |
| Hospital RFP strength | Translated EU deck | US RFP stack with predicate-first cover |
GMA does not publish a client name, a leaked number, or a city-level identifier without explicit written opt-in from the client and, where regulated submissions are involved, from the client's regulatory counsel. The case profile above is a composite drawn from corridor patterns across Swiss-headquartered medtech holdings with German production and Austrian R&D entering the US under the MDR-to-FDA bridge. Specific outcome numbers are not published. Named case studies are added as opt-in is secured.
No legal services, no tax structuring, no immigration or visa work, no banking introductions, no regulatory licensing or 510(k) submission preparation, no fiduciary services, no IP filing, no contract drafting, no M&A transaction work. FDA submission was carried by the in-house regulatory affairs lead and a US FDA submission specialist. Legal and tax structuring was carried by Swiss counsel, German counsel, and US counsel in parallel.
Is this a real client? No. This is an anonymized composite profile drawn from corridor patterns across Swiss medtech holdings entering the United States. No single client is named, no leaked numbers are published, and no neighborhood-level location is used.
Why anonymized? GMA publishes case studies only after explicit client opt-in. Until that opt-in is secured, profiles are written as anonymized composites so the structural pattern is clear without exposing client identity, contract terms, or regulated submission detail.
Can you do similar work for us? Yes if GMA fits the corridor shape: a DACH medtech holding entering the US under the MDR-to-FDA bridge, with a US-facing website, offer, proof, and follow-up not yet aligned to FDA submission posture and US hospital procurement evaluation. Start with an inquiry screening to scope fit.
How does this engagement start? Inquiry screening, scoped against the structural file. If the file fits, GMA proposes a Cross-Border Marketing Build with optional roll into Global Marketing Partnership. Pricing is discussed after GMA sees the company, market, and work needed.
If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | The frame should separate the visible symptom from the real reason the buyer is not moving. |
| What may be unclear | It prevents translation, traffic, or a new sales deck from being treated as the fix when the market still does not understand the company. |
| What to inspect | Use it to sort the symptom, buyer doubt, proof gap, and cost of doing nothing. |
| Next step | Apply the frame to one route or one buyer decision, then move to /engagements/ or /contact/#inquiry if execution is needed. |